Active substance

Results for the substance ivacaftor tezacaftor elexacaftor

4 results

About this active substance

The combination of ivacaftor, tezacaftor, and elexacaftor is used for the treatment of cystic fibrosis in patients with specific CFTR gene mutations. It works by improving the function of the CFTR protein, facilitating chloride transport and reducing disease symptoms.

The medication is taken orally, usually once daily with fat-containing food, as directed by a doctor. It is important to follow the treatment regimen to achieve the best results.

Side effects may include headache, nausea, diarrhea, or skin rashes. In rare cases, severe hepatic reactions or elevated liver enzymes may occur.

This combination is not recommended for patients with hypersensitivity to any of the components or severe hepatic impairment.